TS-13 (antioxidant)

2024: Product Announcement

Russian scientists from Novosibirsk have created a unique water-soluble antioxidant TS-13, which has no analogues in the world. This became known in August 2024. The drug is able to significantly improve the process of chemotherapy in cancer, reducing the negative impact on healthy cells of the body.

According to TASS, the development belongs to specialists from the Novosibirsk State Pedagogical University and the Federal Research Center for Fundamental and Translational Medicine. The main feature of the new antioxidant is its ability to effectively mitigate undesirable general and cardiotoxic manifestations of antitumor anthracycline therapy.

Unsplash

Studies conducted on laboratory animals have shown high TS-13 efficiency. In rats, antitumor doxorubicin resulted in a 21% reduction in body weight and cardiac impairment in all parameters. However, animals treated concomitantly with doxorubicin with a novel antioxidant showed less weight loss and a significant improvement in cardiac functional activity.

The developers claim that TS-13 not only reduces the toxic effects of doxorubicin on the heart, but also enhances the anti-tumor activity of this agent. This unique property sets the drug apart from other antioxidants used in oncology.

In the near future, scientists from Novosibirsk State Pedagogical University and the Federal Research Center for Fundamental and Translational Medicine plan to start preclinical trials of the TS-13, the university said in mid-August 2024. The successful completion of this stage will allow you to move to clinical research and in the future introduce the drug into medical practice.^[1]

Notes